HUMA icon

Humacyte

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 80%
Negative

Neutral
Zacks Investment Research
yesterday
Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors
The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.79, representing a +1.7% change from its previous close.
Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors
Neutral
Zacks Investment Research
8 days ago
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $1.65, indicating a -33.67% shift from the previous trading day.
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
Neutral
GlobeNewsWire
8 days ago
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering
DURHAM, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it entered into a securities purchase agreement with certain fundamental institutional investors to purchase approximately $60.0 million worth of its common stock and warrants in an oversubscribed registered direct offering.
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering
Neutral
GlobeNewsWire
9 days ago
Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™
- Results published in Oxford Academic's Military Medicine Journal - - After up to 18 months of follow-up patients were observed to have zero infections, amputations or deaths and a high rate of patency - DURHAM, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication in Oxford Academic's Military Medicine of positive long-term results from its humanitarian program using Symvess to treat wartime vascular trauma injuries in Ukraine.
Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™
Positive
Zacks Investment Research
14 days ago
Humacyte, Inc. (HUMA) Outperforms Broader Market: What You Need to Know
Humacyte, Inc. (HUMA) concluded the recent trading session at $1.76, signifying a +1.15% move from its prior day's close.
Humacyte, Inc. (HUMA) Outperforms Broader Market: What You Need to Know
Neutral
GlobeNewsWire
16 days ago
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
– Patent covers esophagus produced using Humacyte's proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into 2041 for the composition of novel bioengineered esophagus – DURHAM, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the allowance of a U.S. Patent covering the composition of a bioengineered esophagus that can be produced using the Company's proprietary regenerative tissue engineering platform.
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
Neutral
Zacks Investment Research
23 days ago
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
Humacyte, Inc. (HUMA) concluded the recent trading session at $1.77, signifying a -4.84% move from its prior day's close.
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
Neutral
GlobeNewsWire
28 days ago
Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)
- Results were published in JACC: Basic to Translational Science - - Publication evaluated coronary tissue engineered vessel (CTEV) as a conduit for CABG in a nonhuman primate model - - All implanted CTEVs remained patent through six months, demonstrated adaptive remodeling, and recellularized with host coronary artery cells – - Humacyte plans to advance CTEV into first-in-human study in CABG - DURHAM, N.C., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication of new preclinical data as part of a study evaluating the coronary tissue engineered vessel (CTEV) as a coronary artery bypass graft conduit in a non-human primate model.
Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)
Neutral
GlobeNewsWire
1 month ago
Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™
- Results were published in the Journal of Vascular Surgery - - Publication described treatment of patients with Symvess who had hospital-acquired iatrogenic injuries or complications of vascular surgical procedures - - Patients treated with Symvess were observed to have high levels of patency, 100% limb salvage, and zero cases of conduit infection - DURHAM, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced publication of outcomes for patients with hospital-acquired vascular complications treated with Symvess in the Journal of Vascular Surgery.
Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™
Neutral
Zacks Investment Research
1 month ago
Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?